SHR-A2102 for Injection

DRUG4 trials

Sponsors

Shanghai Hengrui Pharmaceutical Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Conditions

Advanced Gynecological MalignancyAdvanced Urothelial CarcinomaAdvanced or Metastatic Non-small Cell Lung CancerMetastatic Cervical CancerRecurrent Cervical Cancer

Phase 1

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

RecruitingNCT06512051

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced or Metastatic Non-small Cell Lung Cancer

Start: 2024-07-30End: 2026-10-31Target: 248Updated: 2025-12-23

Phase 2

A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy

RecruitingNCT06654440

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Gynecological Malignancy

Start: 2024-11-15End: 2026-10-31Target: 100Updated: 2024-12-10

Phase 3

A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

RecruitingNCT06738251

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Urothelial Carcinoma

Start: 2025-02-12End: 2027-09-30Target: 402Updated: 2025-07-17

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

Not yet recruitingNCT07418749

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Metastatic Cervical Cancer, Recurrent Cervical Cancer

Start: 2026-03-01End: 2028-12-01Target: 398Updated: 2026-02-18